Delivery Order SPE2DB24D2100-SPE2DB25FBGHA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $35,990.01. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a contract ceiling value of $4,745.90. This is a firm fixed price delivery order with no set-aside designation, awarded through open competition to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitive, non-set-aside delivery order carries a ceiling value of $5,838.82 under a firm fixed price arrangement, with an ultimate completion date of September 10, 2025. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $4,477.99 and an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $4,134.12. This is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 with a ceiling value of $4,186.92. This competitive, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by September 11, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a $3,137.60 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and was awarded without a set-aside designation through competitive procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $5,709.71 and an ultimate completion date of August 25, 2025. The contract represents a non-competitive set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGHADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of approximately $25.3K. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures, and scheduled for completion by September 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and federal medical procurement needs. The Ondansetron ODT tablets represent a critical pharmaceutical commodity within this broader contract vehicle, supporting antiemetic treatment requirements across the Department of Defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.3k | 9/11/25 |